Allied Market Research published a report, titled, ‘Graft Versus Host Disease Market by Product Type (Corticosteroids, Monoclonal antibodies, Immunosuppressants, Others), by Treatment Type (Acute GVHD, Chronic GVHD), by End Use (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031.’ According to the report, the global graft versus host disease industry was estimated at $3.0 billion in 2021, and is anticipated to hit $10.4 billion by 2031, registering a CAGR of 13.5% from 2022 to 2031.
The overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.
Download Sample Report– https://www.alliedmarketresearch.com/request-sample/12294
The global graft versus host disease market was valued at $3.0 billion in 2021, and is projected to reach $10.4 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT).
- A sharp decline in the number of transplantation procedures.
- The fact that it requires the routine use of reusable equipment with close contact with patients impacted the global graft versus host disease market negatively, especially during the initial period.
- However, the market has already gotten back on track.
Get detailed COVID-19 impact analysis on the Graft Versus Host Disease Market- https://www.alliedmarketresearch.com/request-for-customization/12294?reqfor=covid
The graft versus host disease market is segmented into Product Type, Treatment Type and End Use.
GVHD has been classically classified on the basis of timing of presentation into acute and chronic using a cutoff of 100 days post-transplant. Acute classic GVHD, occurs within 100 days of transplantation with classical clinical features of acute GVHD. Whereas chronic GVHD, occurs after 100 days of transplant with classic clinical features of chronic GVHD. Overlap syndrome may occur at any time post-transplant with features of both acute and chronic GvHD.
Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogenic hematopoietic stem-cell transplantation, and thus the focus of much ongoing research. A systematic therapy approach is still lacking despite significant progress in the understanding of the pathophysiology, diagnosis, and predisposing factors for both acute and chronic forms of the condition. There is good evidence for initial treatment of both acute and chronic forms of the disease with corticosteroid therapy. However, the most effective approach to steroid-refractory disease remains controversial.
By product, the graft versus host disease market size is segmented into corticosteroids, monoclonal antibodies, immunosuppressants, and others. The immunosuppressants segment was the highest revenue contributor to the market in 2021. Owing to surge in number of targeted drug therapy for the treatment of acute and chronic GVHD with the use of immunosuppressants and the rise in number of populations suffering from various disease such as cardiovascular disease, cancer and nephrological disorder contributes to the growth of graft versus host disease market size.
By type, the graft versus host disease market share is segmented into acute and chronic GVHD. The acute GVHD segment was the highest revenue contributor to the market, owing to rise in geriatric population, increase in prevalence of graft versus host disease, rise in number of allogeneic transplantations.
By end use, the hospital pharmacies segment was the highest revenue contributor to the market owing to increase in demand for transplantation drugs due to surge in the number of allogeneic transplantations. For instance, most transplant patients take between 5 and 15 medications daily, with doses due one to four times daily, which contribute in the growth in demand for graft versus host disease market significantly.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/12294
Graft Versus Host Disease Market Report Highlights
|By Product Type||
|By Treatment Type||
|By End Use||
|Key Market Players||Sanofi, Novartis AG, Merck & Co., Abbvie Inc, Pfizer Inc., Accord Healthcare Limited, Bristol Myer Squibb, Asahi Kasei Corporation, Glaxosmithkline plc, Incyte Corporation|
FREQUENTLY ASKED QUESTIONS?
Q1. What are the upcoming trends of Graft Versus Host Disease Market in the world?
Q2. Which is the largest regional market for Graft Versus Host Disease?
Q3. What is the estimated industry size of Graft Versus Host Disease?
Q4. Which are the top companies to hold the market share in Graft Versus Host Disease?
Q5. Which factors might impact the Graft Versus Host Disease market negatively?
Q6. Which is the most utilized type of drug for treating graft versus host disease?
Q7. What are the key strategies implemented by key players operating in graft versus host disease market?
Q8. Which is the fastest regional market for Graft Versus Host Disease?
𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:
𝐀𝐧𝐭𝐢𝐧𝐮𝐜𝐥𝐞𝐚𝐫 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐞𝐬𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐒𝐢𝐧𝐠𝐥𝐞 𝐂𝐞𝐥𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐈𝐦𝐦𝐮𝐧𝐨𝐡𝐢𝐬𝐭𝐨𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐓𝐞𝐧𝐝𝐨𝐧 𝐑𝐞𝐩𝐚𝐢𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 2031
𝐎𝐫𝐭𝐡𝐨𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 – 20231
Hospital Beds Market Global Opportunity Analysis and Industry Forecast to 2031